COVID-19 and its implications for thrombosis and anticoagulation

Blood - Tập 135 - Trang 2033-2040 - 2020
Jean M. Connors1, Jerrold H. Levy2,3,4
1Hematology Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
2Department of Anesthesiology, Durham, NC
3Division of Critical Care Medicine, Durham, NC
4Department of Surgery, Division of Cardiothoracic Surgery, Duke University School of Medicine, Durham, NC

Tóm tắt

Abstract Severe acute respiratory syndrome coronavirus 2, coronavirus disease 2019 (COVID-19)-induced infection can be associated with a coagulopathy, findings consistent with infection-induced inflammatory changes as observed in patients with disseminated intravascular coagulopathy (DIC). The lack of prior immunity to COVID-19 has resulted in large numbers of infected patients across the globe and uncertainty regarding management of the complications that arise in the course of this viral illness. The lungs are the target organ for COVID-19; patients develop acute lung injury that can progress to respiratory failure, although multiorgan failure can also occur. The initial coagulopathy of COVID-19 presents with prominent elevation of D-dimer and fibrin/fibrinogen-degradation products, whereas abnormalities in prothrombin time, partial thromboplastin time, and platelet counts are relatively uncommon in initial presentations. Coagulation test screening, including the measurement of D-dimer and fibrinogen levels, is suggested. COVID-19–associated coagulopathy should be managed as it would be for any critically ill patient, following the established practice of using thromboembolic prophylaxis for critically ill hospitalized patients, and standard supportive care measures for those with sepsis-induced coagulopathy or DIC. Although D-dimer, sepsis physiology, and consumptive coagulopathy are indicators of mortality, current data do not suggest the use of full-intensity anticoagulation doses unless otherwise clinically indicated. Even though there is an associated coagulopathy with COVID-19, bleeding manifestations, even in those with DIC, have not been reported. If bleeding does occur, standard guidelines for the management of DIC and bleeding should be followed.

Tài liệu tham khảo

Layton, 2017, Breaking the chain of zoonoses through biosecurity in livestock, Vaccine, 35, 5967, 10.1016/j.vaccine.2017.07.110 Wu, 2020, A new coronavirus associated with human respiratory disease in China [published correction appears in Nature. 2020;580(7803):E7], Nature, 579, 265, 10.1038/s41586-020-2008-3 Hulswit, 2016, Coronavirus spike protein and tropism changes, Adv Virus Res, 96, 29, 10.1016/bs.aivir.2016.08.004 Lu, 2020, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet, 395, 565, 10.1016/S0140-6736(20)30251-8 Schnittler, 2003, Viral hemorrhagic fever--a vascular disease?, Thromb Haemost, 89, 967, 10.1055/s-0037-1613397 Iba, 2019, The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases, Thromb Res, 179, 11, 10.1016/j.thromres.2019.04.030 Iba, 2019, Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH, J Thromb Haemost, 17, 415, 10.1111/jth.14354 Woei-A-Jin, 2014, Procoagulant tissue factor activity on microparticles is associated with disease severity and bacteremia in febrile urinary tract infections, Thromb Res, 133, 799, 10.1016/j.thromres.2014.03.007 Gould, 2016, Extracellular histones increase tissue factor activity and enhance thrombin generation by human blood monocytes, Shock, 46, 655, 10.1097/SHK.0000000000000680 Iba, 2018, Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis, J Thromb Haemost, 16, 231, 10.1111/jth.13911 Suzuki, 2018, A re-evaluation of the D-dimer cut-off value for making a diagnosis according to the ISTH overt-DIC diagnostic criteria: communication from the SSC of the ISTH, J Thromb Haemost, 16, 1442, 10.1111/jth.14134 Iba, 2019, Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation, J Thromb Haemost, 17, 1989, 10.1111/jth.14578 Taylor, 2001, Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation, Thromb Haemost, 86, 1327, 10.1055/s-0037-1616068 Iba, 2019, Proposal of a two-step process for the diagnosis of sepsis-induced disseminated intravascular coagulation, J Thromb Haemost, 17, 1265, 10.1111/jth.14482 Tang, 2020, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J Thromb Haemost, 18, 844, 10.1111/jth.14768 Tang, 2020, Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J Thromb Haemost, 18, 1094, 10.1111/jth.14817 Johns Hopkins University . Coronavirus Resource Center. https://coronavirus.jhu.edu/map.html. Accessed 25 April 2020. Chen, 2020, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet, 395, 507, 10.1016/S0140-6736(20)30211-7 Wang, 2020, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA, 323, 1061, 10.1001/jama.2020.1585 Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 395, 1054, 10.1016/S0140-6736(20)30566-3 Guan, 2020, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, 382, 1708, 10.1056/NEJMoa2002032 Metlay, 2019, Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America, Am J Respir Crit Care Med, 200, e45, 10.1164/rccm.201908-1581ST Engelmann, 2013, Thrombosis as an intravascular effector of innate immunity, Nat Rev Immunol, 13, 34, 10.1038/nri3345 Delabranche, 2017, Immunohaemostasis: a new view on haemostasis during sepsis, Ann Intensive Care, 7, 117, 10.1186/s13613-017-0339-5 Jackson, 2019, Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms, Blood, 133, 906, 10.1182/blood-2018-11-882993 Smith, 2006, Polyphosphate modulates blood coagulation and fibrinolysis, Proc Natl Acad Sci USA, 103, 903, 10.1073/pnas.0507195103 Subramaniam, 2017, Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development, Blood, 129, 2291, 10.1182/blood-2016-11-749879 Noubouossie, 2019, Neutrophils: back in the thrombosis spotlight, Blood, 133, 2186, 10.1182/blood-2018-10-862243 Rittirsch, 2008, Harmful molecular mechanisms in sepsis, Nat Rev Immunol, 8, 776, 10.1038/nri2402 Iba, 2019, Derangement of the endothelial glycocalyx in sepsis, J Thromb Haemost, 17, 283, 10.1111/jth.14371 Semeraro, 2018, Platelet drop and fibrinolytic shutdown in patients with sepsis, Crit Care Med, 46, e221, 10.1097/CCM.0000000000002919 Levy, 2018, Antifibrinolytic therapy and perioperative considerations, Anesthesiology, 128, 657, 10.1097/ALN.0000000000001997 Iba, 2018, Prediction of early death in patients with sepsis-associated coagulation disorder treated with antithrombin supplementation, Clin Appl Thromb Hemost, 24, 145S, 10.1177/1076029618797474 Kienast, 2006, Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation, J Thromb Haemost, 4, 90, 10.1111/j.1538-7836.2005.01697.x Yamakawa, 2019, Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis, Crit Care, 23, 302, 10.1186/s13054-019-2587-2 Chen, Clinical and immunologic features in severe and moderate coronavirus disease 2019 [published online ahead of print 27 March 2020], J Clin Invest Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5 Levi, 2018, How I treat disseminated intravascular coagulation, Blood, 131, 845, 10.1182/blood-2017-10-804096 Lippi, 2014, Causes of elevated D-dimer in patients admitted to a large urban emergency department, Eur J Intern Med, 25, 45, 10.1016/j.ejim.2013.07.012 Mehta, 2020, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet, 395, 1033, 10.1016/S0140-6736(20)30628-0 Ranucci, The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome [published online ahead of print 17 April 2020], J Thromb Haemost Saffarzadeh, 2012, Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones, PLoS One, 7, e32366, 10.1371/journal.pone.0032366 Ferrario, 2005, Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2, Circulation, 111, 2605, 10.1161/CIRCULATIONAHA.104.510461 Varga, Endothelial cell infection and endotheliitis in COVID-19 [published online ahead of print 20 April 2020], Lancet Stein, 2004, Pulmonary thromboembolism in Asians/Pacific Islanders in the United States: analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census, Am J Med, 116, 435, 10.1016/j.amjmed.2003.11.020 Zakai, 2011, Racial differences in venous thromboembolism, J Thromb Haemost, 9, 1877, 10.1111/j.1538-7836.2011.04443.x Danzi, Acute pulmonary embolism and COVID-19 pneumonia: a random association? [published online ahead of print 30 March 2020], Eur Heart J Xie, 2020, COVID-19 complicated by acute pulmonary embolism. Radiology, Cardiothoracic Imaging, 2, e200067, 10.1148/ryct.2020200067 Tian, 2020, Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer, J Thorac Oncol, 15, 700, 10.1016/j.jtho.2020.02.010 Klok, Incidence of thrombotic complications in critically ill ICU patients with COVID-19 [published online ahead of print 10 April 2020], Thromb Res Helms, , High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study, Intensive Care Med Poissy, Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence [published online ahead of print 24 April 2020], Circulation Bikdeli, , COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up, J Am Coll Cardiol Pannucci, 2018, Enoxaparin 40 mg per day is inadequate for venous thromboembolism prophylaxis after thoracic surgical procedure, Ann Thorac Surg, 106, 404, 10.1016/j.athoracsur.2018.02.085 Wang, 2014, Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients, Thromb Haemost, 111, 88, 10.1160/TH13-01-0042 Wada, 2013, Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines, J Thromb Haemost, 11, 761, 10.1111/jth.12155 Lin, 2020, Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia, Emerg Microbes Infect, 9, 727, 10.1080/22221751.2020.1746199 Iba, 2019, Advance in the management of sepsis-induced coagulopathy and disseminated intravascular coagulation, J Clin Med, 8, 10.3390/jcm8050728 Vicenzi, 2004, Coronaviridae and SARS-associated coronavirus strain HSR1, Emerg Infect Dis, 10, 413, 10.3201/eid1003.030683 Du, 2007, Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity, Biochem Biophys Res Commun, 359, 174, 10.1016/j.bbrc.2007.05.092 Kam, 2009, Cleavage of the SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro, PLoS One, 4, e7870, 10.1371/journal.pone.0007870 Smyth, 2009, Platelet functions beyond hemostasis, J Thromb Haemost, 7, 1759, 10.1111/j.1538-7836.2009.03586.x Levy, 2015, How I use fibrinogen replacement therapy in acquired bleeding, Blood, 125, 1387, 10.1182/blood-2014-08-552000 Thachil, 2020, ISTH interim guidance on recognition and management of coagulopathy in COVID-19, J Thromb Haem, 18, 1023, 10.1111/jth.14810
Thông tin
Thông tin xuất bản

Blood

Tập 135

2033-2040

Thông tin tác giả